Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: Pharmacoeconomic aspects

  • Authors: Riazhenov VV1, Abuzarova GR2, Gorokhova SG1, Emchenko IV1, Matveev NV3
  • Affiliations:
    1. Первый Московский государственный медицинский университет им. И.М. Сеченова
    2. 1Центр паллиативной помощи онкологическим больным МНИОИ им. П.А. Герцена
    3. Российский национальный исследовательский медицинский университет им Н.И. Пирогова, Москва
  • Issue: Vol 86, No 2 (2014)
  • Pages: 63-68
  • Section: Editorial
  • URL: https://journals.rcsi.science/0040-3660/article/view/31446
  • ID: 31446

Cite item

Full Text

Abstract

AIM: To make a comparative clinical and economic assessment of a transdermal therapeutic system (TTS) for fendivia and traditional opioid analgesics in patients with malignant neoplasms (MN) during palliative care. Materials and methods. Pharmacoeconomic analysis of opioid analgesics used in patients with MN during analgesic therapy was made using the cost-effectiveness analysis in the framework of a budget impact analysis (BIA)/RESULTS: The assessment of the medical cost structure in the fendivia and morphine groups (100 patients in each group), which was made in the framework of BIA, demonstrated that the cost of pharmacotherapy in the fendivia group was comparable with that of an ambulance call for additional analgesia and correction of the side effects of performed therapy (615,804.00 and 645,337.60 rbl. monthly, respectively). At the same time, in the morphine group the cost of an ambulance call was more than 20 times that of pharmacotherapy (2,117,514.00 and 93,120.00 rbl. monthly, respectively). Thus, the total savings from applying the fendivia TTS in the group of 100 patients ranged up to 949,492.40 rbl. monthly/CONCLUSION: The application of the fendivia TTS is clinically and pharmacoeconomically valid and leads to a considerable reduction in public health care costs.

About the authors

V V Riazhenov

Первый Московский государственный медицинский университет им. И.М. Сеченова

G R Abuzarova

1Центр паллиативной помощи онкологическим больным МНИОИ им. П.А. Герцена

S G Gorokhova

Первый Московский государственный медицинский университет им. И.М. Сеченова

I V Emchenko

Первый Московский государственный медицинский университет им. И.М. Сеченова

N V Matveev

Российский национальный исследовательский медицинский университет им Н.И. Пирогова, Москва

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Состояние онкологической помощи населению России в 2012 году. М: ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России 2013; 231.
  2. Абузарова Г., Данилова Т. Промедол в терапии онкологической боли: не пора ли забыть старый препарат? Врач 2011; 12: 75-77.
  3. WHO. Cancer pain relief: with a guide to opioid availability 2nd ed. Geneva: WHO 199; 63.
  4. Radbruch L., Elsner F. Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 2004; 53: 23-29.
  5. Marier J., Lor M., Potvin D. et al. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006; 46 (6): 642-653.
  6. Varvel J., Shafer S., Hwang S. et al. Absorbtion characteristics of transdermally administered fentanyl. Anesthesilogy 1989; 43: 155-162.
  7. Пчелинцев М., Абузарова Г. Трансдермальные терапевтические системы с фентанилом при хронической. Врач 2011; 6: 39-42.
  8. Allan L., Richarz U., Simpson K., Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine 2005; 30 (22): 2484-2490.
  9. Clark A.J., Ahmedzai S.H., Allan L.G. et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004; 20 (9): 1419-1428.
  10. Mystakidou K., Parpa E., Tsilika E. et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain 2004; 5: 119-132.
  11. Payne R., Mathias S.D., Pasta D.J. et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. Clin Oncol 1998; 16: 1588-1593.
  12. Kress H.G., Von der Laage D., Hoerauf K.H. et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage 2008; 36 (3): 268-279.
  13. Cohen J.P., Stolk E., Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law 2008; 33 (2): 225-247.
  14. Ряженов В.В., Горохова С.Г., Бунятян Н.Д. Анализ влияния на бюджет: особенности применения метода. Фармация 2011; 1: 41-44.
  15. Koyyalagunta D., Bruera E., Solanki D.R. et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012; 15 (3 Suppl): ES39-58.
  16. Снегова Е.А. Фармакоэкономическое обоснование применения дюрогезика для купирования интенсивной боли у онкологических больных в амбулаторных и стационарных условиях. Новые лекарственные препараты 2004; 5: 44-46.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies